meta
|
COVID-19
Dynamic meta-analysis of evidences about drug efficacy and safety
adjuvant therapies
anti-inflammatoty and immuno-therapy
antiviral and associated therapy
ASC09/ritonavir
azithromycin
azvudine
baloxavir marboxil
carrimycin
chloroquine and derivatives
chloroquine
hydroxychloroquine
danoprevir / ritonavir
darunavir cobicistat
darunavir/cobicistat plus chloroquine
doxycycline
favipiravir
fluvoxamine
hydroxychloroquine plus macrolides
ivermectin
leronlimab
lopinavir / ritonavir plus ribavirin
lopinavir/ritonavir
lopinavir/ritonavir plus chloroquine
lopinavir/ritonavir plus interferon ß-1a
lopinavir/ritonavir, ribavirin and interferon beta-1b
meplazumab
nitazoxanide
oseltamivir
oseltamivir plus chloroquin
remdesivir
Renin-angiotensin-system-acting agents
angiotensin converting enzyme inhibitors (ACEIs)
angiotensin receptor blockers (ARBs)
angiotensin-(1-7)
discontinuation of ACEI/ARB
RAS blocker withdrawal
rhACE2
ribavirin
ritonavir
sofosbuvir and daclatasvir
tenofovir/emtricitabine
tenofovir/emtricitabine plus hydroxychloroquine
tranexamic acid
triazavirin
umifenovir (arbidol)
control
honey
miscellaneous
vaccines
COVID-19
COVID 19 hospitalized
COVID 19 all comers
COVID-19 mild to moderate
COVID-19 severe or critically
COVID 19 outpatients
COVID-19 prophylaxis
infections other than COVID-19
preventing respiratory virus transmission
Meta-analysis results for all treatments
Treatment relative effect with 95% CI; and degree of certainty (adaptated from GRADE).
method
Treament
Trials
Summary
Endpoints
death or transfer to ICU
deaths
deaths (time to event analysis only)
clinical deterioration
clinical improvement
clinical improvement (14-day)
clinical improvement (21-day)
clinical improvement (28-day)
clinical improvement (7-day)
clinical improvement (time to event analysis only)
conversion to SARS-CoV- 2–positive status via NP swab
death or ventilation
hospital discharge
hospitalization
Influenza-like infection
laboratory-confirmed Covid-19
new illness compatible with Covid-19
PCR-negative conversion
PCR-negative conversion (14-day)
PCR-negative conversion (7-day)
PCR-negative conversion (time to event analysis only)
radiologic improvement (14-day)
radiologic improvement (7-day)
ventilation
ventilation (time to event analysis only)
ICU admission
severe COVID-19 occurrence
time to recovery
AE leading to drug discontinuation
cardiac arrest
serious adverse events
abnormal ECG findings
adverse events
arrhythmia
deep vein thrombosis
elevated liver enzymes
hyperbilirubinemia
long QT
pulmonary embolism
renal impairment
ventricular arrhythmia
core analysis (OBS if no RCT)
RCTs only
all (RCT+OBS)
clinical deterioration
clinical improvement
deaths
PCR-negative conversion
chloroquine and derivatives
5
-
8.18
[0.32; 209.71], 3 RCTs, I2=82%
inconclusive result
-
-
ASC09/ritonavir
0
-
-
-
-
azithromycin
0
-
-
-
-
azvudine
0
-
-
-
-
baloxavir marboxil
0
-
-
-
-
carrimycin
0
-
-
-
-
danoprevir / ritonavir
0
-
-
-
-
darunavir cobicistat
0
-
-
-
-
darunavir/cobicistat plus chloroquine
0
-
-
-
-
doxycycline
0
-
-
-
-
favipiravir
0
-
-
-
-
fluvoxamine
0
-
-
-
-
hydroxychloroquine plus macrolides
0
-
-
-
-
ivermectin
0
-
-
-
-
leronlimab
0
-
-
-
-
lopinavir / ritonavir plus ribavirin
0
-
-
-
-
lopinavir/ritonavir
0
-
-
-
-
lopinavir/ritonavir plus chloroquine
0
-
-
-
-
lopinavir/ritonavir plus interferon ß-1a
0
-
-
-
-
lopinavir/ritonavir, ribavirin and interferon beta-1b
0
-
-
-
-
meplazumab
0
-
-
-
-
nitazoxanide
0
-
-
-
-
oseltamivir
0
-
-
-
-
oseltamivir plus chloroquin
0
-
-
-
-
remdesivir
0
-
-
-
-
Renin-angiotensin-system-acting agents
0
-
-
-
-
ribavirin
0
-
-
-
-
ritonavir
0
-
-
-
-
sofosbuvir and daclatasvir
0
-
-
-
-
tenofovir/emtricitabine
0
-
-
-
-
tenofovir/emtricitabine plus hydroxychloroquine
0
-
-
-
-
tranexamic acid
0
-
-
-
-
triazavirin
0
-
-
-
-
umifenovir (arbidol)
0
-
-
-
-